Marilyn Huestis
#107,118
Most Influential Person Now
American toxicologist
Marilyn Huestis's AcademicInfluence.com Rankings
Marilyn Huestismedical Degrees
Medical
#1420
World Rank
#1757
Historical Rank
Toxicology
#9
World Rank
#11
Historical Rank
Download Badge
Medical
Marilyn Huestis's Degrees
- Masters Forensic Science George Washington University
- Bachelors Chemistry University of Maryland, College Park
Why Is Marilyn Huestis Influential?
(Suggest an Edit or Addition)According to Wikipedia, Marilyn Ann Huestis is an American toxicologist researching the effects of illicit drugs on the body, brain, and in utero. She was chief of the chemistry and drug metabolism section at the National Institute on Drug Abuse.
Marilyn Huestis's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Human Cannabinoid Pharmacokinetics (2007) (797)
- Neuropsychological performance in long-term cannabis users. (2001) (660)
- Matrix effect in bio-analysis of illicit drugs with LC-MS/MS: Influence of ionization type, sample preparation, and biofluid (2003) (563)
- Synthetic cannabinoids: epidemiology, pharmacodynamics, and clinical implications. (2014) (546)
- Early-onset cannabis use and cognitive deficits: what is the nature of the association? (2003) (526)
- Cannabis effects on driving skills. (2013) (490)
- Blockade of effects of smoked marijuana by the CB1-selective cannabinoid receptor antagonist SR141716. (2001) (477)
- Reversible and regionally selective downregulation of brain cannabinoid CB1 receptors in chronic daily cannabis smokers (2012) (471)
- Blood cannabinoids. I. Absorption of THC and formation of 11-OH-THC and THCCOOH during and after smoking marijuana. (1992) (447)
- Oral fluid testing for drugs of abuse. (2009) (339)
- The Maternal Lifestyle Study: drug use by meconium toxicology and maternal self-report. (2001) (307)
- Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients: effects on the neonatal abstinence syndrome. (2005) (290)
- The Infant Development, Environment, and Lifestyle Study: Effects of Prenatal Methamphetamine Exposure, Polydrug Exposure, and Poverty on Intrauterine Growth (2006) (257)
- Pharmacokinetics and metabolism of the plant cannabinoids, delta9-tetrahydrocannabinol, cannabidiol and cannabinol. (2005) (234)
- Methamphetamine and amphetamine pharmacokinetics in oral fluid and plasma after controlled oral methamphetamine administration to human volunteers. (2003) (233)
- Methamphetamine and Other Substance Use During Pregnancy: Preliminary Estimates From the Infant Development, Environment, and Lifestyle (IDEAL) Study (2006) (218)
- Nicotine Enhances Visuospatial Attention by Deactivating Areas of the Resting Brain Default Network (2007) (198)
- Oxytocin by intranasal and intravenous routes reaches the cerebrospinal fluid in rhesus macaques: determination using a novel oxytocin assay (2018) (198)
- Relationship of Delta 9-tetrahydrocannabinol concentrations in oral fluid and plasma after controlled administration of smoked cannabis. (2004) (193)
- Plasma cannabinoid pharmacokinetics following controlled oral delta9-tetrahydrocannabinol and oromucosal cannabis extract administration. (2011) (188)
- Cannabidiol Adverse Effects and Toxicity. (2019) (184)
- Prenatal methamphetamine use and neonatal neurobehavioral outcome. (2008) (183)
- Primary outcome indices in illicit drug dependence treatment research: systematic approach to selection and measurement of drug use end-points in clinical trials. (2012) (179)
- Cannabis effects on driving lateral control with and without alcohol. (2015) (172)
- Interpretation of Oral Fluid Tests for Drugs of Abuse (2007) (169)
- Cognitive Measures in Long‐Term Cannabis Users (2002) (169)
- Guidelines for research on drugged driving. (2008) (167)
- Drug abuse's smallest victims: in utero drug exposure. (2002) (153)
- Methadone Maintenance and Breastfeeding in the Neonatal Period (2008) (153)
- Characterization of the absorption phase of marijuana smoking (1992) (152)
- Differentiating new marijuana use from residual drug excretion in occasional marijuana users. (1998) (151)
- Oral fluid as a diagnostic tool (2004) (150)
- Single and multiple doses of rimonabant antagonize acute effects of smoked cannabis in male cannabis users (2007) (145)
- Identification of recent cannabis use: whole-blood and plasma free and glucuronidated cannabinoid pharmacokinetics following controlled smoked cannabis administration. (2011) (141)
- Acute and residual effects of marijuana: Profiles of plasma THC levels, physiological, subjective, and performance measures (1990) (136)
- Cannabis withdrawal among non-treatment-seeking adult cannabis users. (2006) (135)
- Bioanalytical procedures for monitoring in utero drug exposure (2007) (134)
- Prenatal Methamphetamine Exposure and Childhood Behavior Problems at 3 and 5 Years of Age (2012) (131)
- Urinary excretion profiles of 11-nor-9-carboxy-delta 9-tetrahydrocannabinol in humans after single smoked doses of marijuana. (1996) (130)
- Neonatal abstinence syndrome in methadone-exposed infants is altered by level of prenatal tobacco exposure. (2004) (130)
- Blood cannabinoids. II: Models for the prediction of time of marijuana exposure from plasma concentrations of Δ9-tetrahydrocannabinol (THC) and 11-nor-9-carboxy-Δ9-tetrahydrocannabinol (THCCOOH) (1992) (130)
- Methamphetamine-induced neurotoxicity is attenuated in transgenic mice with a null mutation for interleukin-6. (2000) (128)
- Reports of Adverse Events Associated with Use of Novel Psychoactive Substances, 2013-2016: A Review. (2017) (124)
- Metabolic Effects of Chronic Cannabis Smoking (2013) (122)
- Phase I and II cannabinoid disposition in blood and plasma of occasional and frequent smokers following controlled smoked cannabis. (2014) (122)
- Impact of prolonged cannabinoid excretion in chronic daily cannabis smokers' blood on per se drugged driving laws. (2013) (121)
- Qualitative confirmation of 9 synthetic cannabinoids and 20 metabolites in human urine using LC-MS/MS and library search. (2013) (119)
- Detection times of marijuana metabolites in urine by immunoassay and GC-MS. (1995) (118)
- Nontargeted SWATH acquisition for identifying 47 synthetic cannabinoid metabolites in human urine by liquid chromatography-high-resolution tandem mass spectrometry (2014) (118)
- Urine drug testing for opioids, cocaine, and metabolites by direct injection liquid chromatography/tandem mass spectrometry. (2003) (116)
- Free and Glucuronide Whole Blood Cannabinoids' Pharmacokinetics after Controlled Smoked, Vaporized, and Oral Cannabis Administration in Frequent and Occasional Cannabis Users: Identification of Recent Cannabis Intake. (2016) (115)
- The Corticotropin Releasing Hormone-1 (CRH1) Receptor Antagonist Pexacerfont in Alcohol Dependence: A Randomized Controlled Experimental Medicine Study (2015) (114)
- Plasma Pharmacokinetics of 3,4-Methylenedioxymethamphetamine After Controlled Oral Administration to Young Adults (2008) (113)
- Neuropharmacology of 3,4-Methylenedioxypyrovalerone (MDPV), Its Metabolites, and Related Analogs. (2017) (112)
- Identifying prenatal cannabis exposure and effects of concurrent tobacco exposure on neonatal growth. (2010) (107)
- Simultaneous quantification of 28 synthetic cathinones and metabolites in urine by liquid chromatography-high resolution mass spectrometry (2013) (106)
- Quitting among non-treatment-seeking marijuana users: reasons and changes in other substance use. (2006) (104)
- Smoked cannabis' psychomotor and neurocognitive effects in occasional and frequent smokers. (2015) (104)
- Subjective and Physiological Effects After Controlled Sativex and Oral THC Administration (2011) (103)
- Simultaneous determination of 40 novel psychoactive stimulants in urine by liquid chromatography-high resolution mass spectrometry and library matching. (2015) (103)
- Controlled Cannabis Vaporizer Administration: Blood and Plasma Cannabinoids with and without Alcohol. (2015) (103)
- Sweat testing for cocaine, codeine and metabolites by gas chromatography-mass spectrometry. (1999) (100)
- Do Delta9-tetrahydrocannabinol concentrations indicate recent use in chronic cannabis users? (2009) (99)
- Prenatal methamphetamine exposure and neonatal neurobehavioral outcome in the USA and New Zealand. (2011) (99)
- Synthetic cannabinoids pharmacokinetics and detection methods in biological matrices (2015) (98)
- Implications of plasma Delta9-tetrahydrocannabinol, 11-hydroxy-THC, and 11-nor-9-carboxy-THC concentrations in chronic cannabis smokers. (2009) (98)
- Plasma and oral fluid pharmacokinetics and pharmacodynamics after oral codeine administration. (2002) (98)
- Cannabinoid concentrations in hair from documented cannabis users. (2007) (97)
- Metabolism of synthetic cannabinoids PB-22 and its 5-fluoro analog, 5F-PB-22, by human hepatocyte incubation and high-resolution mass spectrometry (2014) (97)
- Relating Blood Concentrations of Tetrahydrocannabinol and Metabolites to Pharmacologic Effects and Time of Marijuana Usage (1993) (96)
- Pentylindole/Pentylindazole Synthetic Cannabinoids and Their 5-Fluoro Analogs Produce Different Primary Metabolites: Metabolite Profiling for AB-PINACA and 5F-AB-PINACA (2015) (95)
- Urinary elimination of 11-nor-9-carboxy-delta9-tetrahydrocannnabinol in cannabis users during continuously monitored abstinence. (2008) (94)
- Major and minor metabolites of cocaine in human plasma following controlled subcutaneous cocaine administration. (2006) (94)
- Direct quantification of cannabinoids and cannabinoid glucuronides in whole blood by liquid chromatography–tandem mass spectrometry (2011) (94)
- Simultaneous quantification of 20 synthetic cannabinoids and 21 metabolites, and semi-quantification of 12 alkyl hydroxy metabolites in human urine by liquid chromatography-tandem mass spectrometry. (2014) (93)
- Quantitative analysis of THC, 11-OH-THC, and THCCOOH in human hair by negative ion chemical ionization mass spectrometry. (1995) (93)
- The dose effects of short-term dronabinol (oral THC) maintenance in daily cannabis users. (2013) (93)
- Extended urinary Delta9-tetrahydrocannabinol excretion in chronic cannabis users precludes use as a biomarker of new drug exposure. (2009) (93)
- Just Say “I Don't”: Lack of Concordance Between Teen Report and Biological Measures of Drug Use (2010) (92)
- Intrauterine growth of infants exposed to prenatal methamphetamine: results from the infant development, environment, and lifestyle study. (2010) (92)
- Duration of detectable methamphetamine and amphetamine excretion in urine after controlled oral administration of methamphetamine to humans. (2002) (92)
- Performance effects of nicotine during selective attention, divided attention, and simple stimulus detection: an fMRI study. (2009) (90)
- Simultaneous quantification of cannabinoids and metabolites in oral fluid by two-dimensional gas chromatography mass spectrometry. (2010) (90)
- Oral fluid as an alternative matrix to monitor opiate and cocaine use in substance-abuse treatment patients. (2007) (88)
- First metabolic profile of XLR-11, a novel synthetic cannabinoid, obtained by using human hepatocytes and high-resolution mass spectrometry. (2013) (88)
- Motor and cognitive outcomes through three years of age in children exposed to prenatal methamphetamine. (2011) (88)
- Psychomotor performance, subjective and physiological effects and whole blood Δ⁹-tetrahydrocannabinol concentrations in heavy, chronic cannabis smokers following acute smoked cannabis. (2012) (87)
- Safety and Pharmacokinetics of Oral Cannabidiol When Administered Concomitantly With Intravenous Fentanyl in Humans (2015) (86)
- Methamphetamine Disposition in Oral Fluid, Plasma, and Urine (2007) (86)
- Correlations of Maternal Buprenorphine Dose, Buprenorphine, and Metabolite Concentrations in Meconium With Neonatal Outcomes (2008) (85)
- Patterns of Methamphetamine Use During Pregnancy: Results from the Infant Development, Environment, and Lifestyle (IDEAL) Study (2009) (85)
- Linear pharmacokinetics of 3,4‐methylenedioxypyrovalerone (MDPV) and its metabolites in the rat: relationship to pharmacodynamic effects (2016) (85)
- Validated method for the simultaneous determination of Delta 9-tetrahydrocannabinol (THC), 11-hydroxy-THC and 11-nor-9-carboxy-THC in human plasma using solid phase extraction and gas chromatography-mass spectrometry with positive chemical ionization. (2003) (84)
- Maternal smoking during pregnancy and infant stress response: Test of a prenatal programming hypothesis (2014) (84)
- Monitoring opiate use in substance abuse treatment patients with sweat and urine drug testing. (2000) (83)
- Urinary excretion half-life of 11-nor-9-carboxy-delta9-tetrahydrocannabinol in humans. (1998) (82)
- Intra- and interindividual variations in urinary concentrations of endogenous gamma-hydroxybutyrate. (2002) (82)
- Simultaneous GC–EI-MS Determination of Δ9-Tetrahydrocannabinol, 11-Hydroxy-Δ9-Tetrahydrocannabinol, and 11-nor-9-Carboxy-Δ9-Tetrahydrocannabinol in Human Urine Following Tandem Enzyme-Alkaline Hydrolysis (2007) (81)
- Transcriptional profiling in the human prefrontal cortex: evidence for two activational states associated with cocaine abuse (2003) (81)
- Current knowledge on cannabinoids in oral fluid. (2014) (80)
- Nabiximols combined with motivational enhancement/cognitive behavioral therapy for the treatment of cannabis dependence: A pilot randomized clinical trial (2018) (80)
- Delta9-tetrahydrocannabinol (THC), 11-hydroxy-THC, and 11-nor-9-carboxy-THC plasma pharmacokinetics during and after continuous high-dose oral THC. (2009) (79)
- Prenatal and postnatal cocaine exposure predict teen cocaine use. (2011) (79)
- Effects of Dose and Route of Administration on Pharmacokinetics of (±)-3,4-Methylenedioxymethamphetamine in the Rat (2009) (78)
- Oral fluid cannabinoids in chronic, daily Cannabis smokers during sustained, monitored abstinence. (2011) (78)
- Cannabinoids in exhaled breath following controlled administration of smoked cannabis. (2013) (78)
- Identification of hydrocodone in human urine following controlled codeine administration. (2000) (78)
- LC-atmospheric pressure chemical ionization-MS/ MS analysis of multiple illicit drugs, methadone, and their metabolites in oral fluid following protein precipitation. (2003) (77)
- A Test of the Cognitive Self-Medication Hypothesis of Tobacco Smoking in Schizophrenia (2013) (75)
- Dose-Related Distribution of Codeine, Cocaine, and Metabolites into Human Hair following Controlled Oral Codeine and Subcutaneous Cocaine Administration (2005) (75)
- Estimating the Time of Last Cannabis Use from Plasma Δ9-Tetrahydrocannabinol and 11-nor-9-Carboxy-Δ9-Tetrahydrocannabinol Concentrations (2005) (74)
- Urine testing for cocaine abuse: metabolic and excretion patterns following different routes of administration and methods for detection of false-negative results. (2003) (74)
- Physiological and Subjective Responses to Controlled Oral 3,4-Methylenedioxymethamphetamine Administration (2008) (74)
- Cannabis effects on driving longitudinal control with and without alcohol (2016) (74)
- First Characterization of AKB-48 Metabolism, a Novel Synthetic Cannabinoid, Using Human Hepatocytes and High-Resolution Mass Spectrometry (2013) (73)
- Effects of prenatal methamphetamine exposure on behavioral and cognitive findings at 7.5 years of age. (2014) (72)
- Psychomotor Function in Chronic Daily Cannabis Smokers during Sustained Abstinence (2013) (72)
- Pharmacokinetics of Cocaine and Metabolites in Human Oral Fluid and Correlation With Plasma Concentrations After Controlled Administration (2010) (71)
- A Mechanism for the Inhibition of Neural Progenitor Cell Proliferation by Cocaine (2008) (70)
- Demographic and Psychosocial Characteristics of Mothers Using Methamphetamine During Pregnancy: Preliminary Results of the Infant Development, Environment, and Lifestyle Study (IDEAL) (2007) (69)
- Clinical sensitivity and specificity of meconium fatty acid ethyl ester, ethyl glucuronide, and ethyl sulfate for detecting maternal drinking during pregnancy. (2015) (68)
- Cannabinoid disposition in oral fluid after controlled smoked, vaporized, and oral cannabis administration. (2017) (67)
- Simultaneous quantification of opiates, cocaine, and metabolites in hair by LC-APCI-MS/MS. (2004) (66)
- Metabolism of Carfentanil, an Ultra-Potent Opioid, in Human Liver Microsomes and Human Hepatocytes by High-Resolution Mass Spectrometry (2016) (66)
- Chronic Exposure to Nicotine Is Associated with Reduced Reward-Related Activity in the Striatum but not the Midbrain (2012) (66)
- Nicotine Metabolite Ratio (3-Hydroxycotinine/Cotinine) in Plasma and Urine by Different Analytical Methods and Laboratories: Implications for Clinical Implementation (2015) (65)
- Simultaneous quantification of Delta9-tetrahydrocannabinol, 11-hydroxy-Delta9-tetrahydrocannabinol, and 11-nor-Delta9-tetrahydrocannabinol-9-carboxylic acid in human plasma using two-dimensional gas chromatography, cryofocusing, and electron impact-mass spectrometry. (2007) (65)
- High-Resolution Mass Spectrometry for Characterizing the Metabolism of Synthetic Cannabinoid THJ-018 and Its 5-Fluoro Analog THJ-2201 after Incubation in Human Hepatocytes. (2016) (65)
- A Study of peptide-peptide interaction by matrix-assisted laser desorption/ionization (2001) (65)
- The cannabinoid CB1 receptor antagonist rimonabant attenuates the hypotensive effect of smoked marijuana in male smokers. (2006) (65)
- New Synthetic Cannabinoids Metabolism and Strategies to Best Identify Optimal Marker Metabolites (2019) (64)
- Simultaneous determination of nicotine, cotinine, norcotinine, and trans-3'-hydroxycotinine in human oral fluid using solid phase extraction and gas chromatography-mass spectrometry. (2005) (64)
- Simultaneous determination of buprenorphine, norbuprenorphine, and buprenorphine-glucuronide in plasma by liquid chromatography-tandem mass spectrometry. (2001) (64)
- Differentiating new cannabis use from residual urinary cannabinoid excretion in chronic, daily cannabis users. (2011) (64)
- Effects of fixed or self-titrated dosages of Sativex on cannabis withdrawal and cravings. (2016) (63)
- Urinary elimination of cocaine metabolites in chronic cocaine users during cessation. (2002) (63)
- Cannabis ( Marijuana ) — Effects on Human Behavior and Performance (2002) (62)
- Disposition of cocaine and its metabolites in human sweat after controlled cocaine administration. (2005) (62)
- Subjective and physiological effects, and expired carbon monoxide concentrations in frequent and occasional cannabis smokers following smoked, vaporized, and oral cannabis administration. (2017) (62)
- Marijuana Neurobiology and Treatment (2008) (62)
- Urinary Pharmacokinetics of Methamphetamine and Its Metabolite, Amphetamine Following Controlled Oral Administration to Humans (2004) (62)
- Cannabis withdrawal in chronic, frequent cannabis smokers during sustained abstinence within a closed residential environment. (2013) (61)
- Concentrations of Methadone in Breast Milk and Plasma in the Immediate Perinatal Period (2007) (60)
- Acute Nicotine Differentially Impacts Anticipatory Valence- and Magnitude-Related Striatal Activity (2013) (60)
- Simultaneous quantification of free and glucuronidated cannabinoids in human urine by liquid chromatography tandem mass spectrometry. (2012) (60)
- Identification of AB-FUBINACA metabolites in human hepatocytes and urine using high-resolution mass spectrometry (2015) (59)
- Nicotine and metabolites in meconium as evidence of maternal cigarette smoking during pregnancy and predictors of neonatal growth deficits. (2010) (59)
- Cannabinoid disposition in oral fluid after controlled smoked cannabis. (2012) (59)
- Synthetic cathinone pharmacokinetics, analytical methods, and toxicological findings from human performance and postmortem cases (2016) (59)
- A liquid chromatography tandem mass spectrometry method for the simultaneous quantification of 20 drugs of abuse and metabolites in human meconium (2009) (59)
- Modern instrumental methods in forensic toxicology. (2007) (58)
- Transcriptional Changes Common to Human Cocaine, Cannabis and Phencyclidine Abuse (2006) (58)
- Validation of the only commercially available immunoassay for synthetic cathinones in urine: Randox Drugs of Abuse V Biochip Array Technology. (2014) (57)
- Concentration profiles of cocaine, pyrolytic methyl ecgonidine and thirteen metabolites in human blood and urine: determination by gas chromatography-mass spectrometry. (2005) (57)
- Cannabinoid stability in authentic oral fluid after controlled cannabis smoking. (2012) (57)
- Sociodemographic Characteristics of Cannabis Smokers and the Experience of Cannabis Withdrawal (2010) (57)
- Simultaneous Determination of Δ9-Tetrahydrocannabinol and 11-nor-9-Carboxy-Δ9-Tetrahydrocannabinol in Human Plasma by Solid-Phase Extraction and Gas Chromatography-Negative Ion Chemical Ionization-Mass Spectrometry (2001) (57)
- Cocaine and metabolite elimination patterns in chronic cocaine users during cessation: plasma and saliva analysis. (2000) (56)
- Developmental and behavioral consequences of prenatal methamphetamine exposure: A review of the Infant Development, Environment, and Lifestyle (IDEAL) study. (2015) (56)
- Identifying new cannabis use with urine creatinine-normalized THCCOOH concentrations and time intervals between specimen collections. (2009) (56)
- Metabolic profiling of new synthetic cannabinoids AMB and 5F-AMB by human hepatocyte and liver microsome incubations and high-resolution mass spectrometry. (2016) (55)
- Prenatal Methamphetamine Exposure and Short-Term Maternal and Infant Medical Outcomes (2012) (55)
- Monitoring cocaine use in substance-abuse-treatment patients by sweat and urine testing. (1999) (55)
- LC–ESI‐MS/MS analysis for the quantification of morphine, codeine, morphine‐3‐β‐D‐glucuronide, morphine‐6‐β‐D‐glucuronide, and codeine‐6‐β‐D‐glucuronide in human urine (2005) (55)
- Tolerance to effects of high-dose oral δ9-tetrahydrocannabinol and plasma cannabinoid concentrations in male daily cannabis smokers. (2013) (55)
- The potential role of oral fluid in antidoping testing. (2014) (54)
- Development and validation of a solid-phase extraction gas chromatography–mass spectrometry method for the simultaneous quantification of methadone, heroin, cocaine and metabolites in sweat (2008) (54)
- High-throughput simultaneous analysis of buprenorphine, methadone, cocaine, opiates, nicotine, and metabolites in oral fluid by liquid chromatography tandem mass spectrometry (2010) (54)
- In Vitro and In Vivo Human Metabolism of Synthetic Cannabinoids FDU-PB-22 and FUB-PB-22 (2016) (54)
- Urinary MDMA, MDA, HMMA, and HMA excretion following controlled MDMA administration to humans. (2009) (53)
- Validated gas chromatographic-negative ion chemical ionization mass spectrometric method for delta(9)-tetrahydrocannabinol in sweat patches. (2004) (52)
- Infant Temperament and High-Risk Environment Relate to Behavior Problems and Language in Toddlers (2011) (52)
- Drug Recognition Expert (DRE) examination characteristics of cannabis impairment. (2016) (52)
- Cannabis in Sport (2011) (52)
- Quantification of nicotine, cotinine, trans-3'-hydroxycotinine, nornicotine and norcotinine in human meconium by liquid chromatography/tandem mass spectrometry. (2008) (52)
- Oral Fluid Drug Testing: Analytical Approaches, Issues and Interpretation of Results. (2019) (52)
- Recommendations for Toxicological Investigation of Drug-Impaired Driving and Motor Vehicle Fatalities-2017 Update. (2018) (51)
- Effects of the Cannabinoid-1 Receptor Antagonist Rimonabant on Psychiatric Symptoms in Overweight People With Schizophrenia: A Randomized, Double-Blind, Pilot Study (2011) (51)
- Oral fluid cannabinoid concentrations following controlled smoked cannabis in chronic frequent and occasional smokers (2013) (50)
- Cannabis (Marijuana) - Effects on Human Performance and Behavior. (2002) (50)
- Effect of Blood Collection Time on Measured Δ9-Tetrahydrocannabinol Concentrations: Implications for Driving Interpretation and Drug Policy. (2016) (50)
- Cannabinoids and metabolites in expectorated oral fluid following controlled smoked cannabis. (2012) (50)
- 25C-NBOMe and 25I-NBOMe metabolite studies in human hepatocytes, in vivo mouse and human urine with high-resolution mass spectrometry. (2017) (49)
- Blood cannabinoids. II. Models for the prediction of time of marijuana exposure from plasma concentrations of delta 9-tetrahydrocannabinol (THC) and 11-nor-9-carboxy-delta 9-tetrahydrocannabinol (THCCOOH) (1992) (49)
- Prenatal methamphetamine exposure and inhibitory control among young school-age children. (2012) (49)
- Excretion of Δ9-Tetrahydrocannabinol in Sweat (2008) (48)
- Cocaine and metabolites urinary excretion after controlled smoked administration. (2007) (48)
- Co-morbidity of substance use disorder and psychopathology in women who use methamphetamine during pregnancy in the US and New Zealand. (2013) (47)
- Maternal methadone dose, placental methadone concentrations, and neonatal outcomes. (2011) (47)
- Simultaneous and sensitive measurement of nicotine, cotinine, trans-3'-hydroxycotinine and norcotinine in human plasma by liquid chromatography-tandem mass spectrometry. (2009) (47)
- Simultaneous quantification of 11 cannabinoids and metabolites in human urine by liquid chromatography tandem mass spectrometry using WAX-S tips (2016) (47)
- Prenatal methamphetamine exposure, home environment, and primary caregiver risk factors predict child behavioral problems at 5 years. (2013) (46)
- Methadone, Cocaine, Opiates, and Metabolite Disposition in Umbilical Cord and Correlations to Maternal Methadone Dose and Neonatal Outcomes (2011) (46)
- Intra- and intersubject whole blood/plasma cannabinoid ratios determined by 2-dimensional, electron impact GC-MS with cryofocusing. (2009) (46)
- On-site test for cannabinoids in oral fluid. (2012) (46)
- Prenatal methamphetamine exposure and neurodevelopmental outcomes in children from 1 to 3 years. (2014) (46)
- Disposition of cannabinoids in oral fluid after controlled around-the-clock oral THC administration. (2010) (46)
- Oral fluid testing: promises and pitfalls. (2011) (45)
- Quantification of six cannabinoids and metabolites in oral fluid by liquid chromatography-tandem mass spectrometry. (2015) (45)
- Maternal Buprenorphine Dose, Placenta Buprenorphine, and Metabolite Concentrations and Neonatal Outcomes (2010) (45)
- A validated gas chromatographic-electron impact ionization mass spectrometric method for methylenedioxymethamphetamine (MDMA), methamphetamine and metabolites in oral fluid. (2006) (45)
- Effects of High-Dose Intravenous Buprenorphine in Experienced Opioid Abusers (2004) (45)
- Prenatal tobacco exposure, biomarkers for tobacco in meconium, and neonatal growth outcomes. (2013) (45)
- Identification of Prenatal Amphetamines Exposure by Maternal Interview and Meconium Toxicology in the Infant Development, Environment and Lifestyle (IDEAL) Study (2009) (45)
- Amphetamine-induced toxicity in dopamine terminals in CD-1 and C57BL/6J mice: complex roles for oxygen-based species and temperature regulation (2001) (44)
- Quantification of cannabinoids and their free and glucuronide metabolites in whole blood by disposable pipette extraction and liquid chromatography-tandem mass spectrometry. (2016) (44)
- Predictive model accuracy in estimating last Δ9-tetrahydrocannabinol (THC) intake from plasma and whole blood cannabinoid concentrations in chronic, daily cannabis smokers administered subchronic oral THC. (2012) (43)
- Simultaneous analysis of buprenorphine, methadone, cocaine, opiates and nicotine metabolites in sweat by liquid chromatography tandem mass spectrometry (2011) (43)
- In vitro, in vivo and in silico metabolic profiling of α-pyrrolidinopentiothiophenone, a novel thiophene stimulant. (2016) (43)
- Relative performance of common biochemical indicators in detecting cigarette smoking. (2011) (43)
- Incorporation of methamphetamine and amphetamine in human hair following controlled oral methamphetamine administration. (2012) (42)
- Cocaine analytes in human hair: evaluation of concentration ratios in different cocaine sources, drug-user populations and surface-contaminated specimens. (2012) (42)
- 4-Methoxy-α-PVP: in silico prediction, metabolic stability, and metabolite identification by human hepatocyte incubation and high-resolution mass spectrometry (2015) (42)
- A validated method for the determination of nicotine, cotinine, trans-3'-hydroxycotinine, and norcotinine in human plasma using solid-phase extraction and liquid chromatography-atmospheric pressure chemical ionization-mass spectrometry. (2006) (42)
- Simultaneous quantification of methadone, cocaine, opiates, and metabolites in human placenta by liquid chromatography-mass spectrometry. (2009) (42)
- Preliminary Buprenorphine Sublingual Tablet Pharmacokinetic Data in Plasma, Oral Fluid, and Sweat During Treatment of Opioid-Dependent Pregnant Women (2011) (41)
- Epigenetic Regulation of Placental NR3C1: Mechanism Underlying Prenatal Programming of Infant Neurobehavior by Maternal Smoking? (2016) (41)
- Examining the relationships between prenatal methamphetamine exposure, early adversity, and child neurobehavioral disinhibition. (2013) (41)
- Fatty Acid Amide Hydrolase Binding in Brain of Cannabis Users: Imaging With the Novel Radiotracer [11C]CURB (2016) (41)
- Postmortem redistribution of Δ9-tetrahydrocannabinol (THC), 11-hydroxy-THC (11-OH-THC), and 11-nor-9-carboxy-THC (THCCOOH). (2011) (41)
- Rimonabant for neurocognition in schizophrenia: A 16-week double blind randomized placebo controlled trial (2012) (41)
- High-resolution mass spectrometric metabolite profiling of a novel synthetic designer drug, N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide (STS-135), using cryopreserved human hepatocytes and assessment of metabolic stability with human liver microsomes. (2015) (41)
- Performance characteristics of the Cozart RapiScan Oral Fluid Drug Testing System for opiates in comparison to ELISA and GC/MS following controlled codeine administration. (2004) (40)
- In vitro stability of free and glucuronidated cannabinoids in blood and plasma following controlled smoked cannabis. (2013) (40)
- Methadone maintenance and long-term lactation. (2008) (40)
- Excretion of methamphetamine and amphetamine in human sweat following controlled oral methamphetamine administration. (2008) (40)
- Estimating Time of Last Oral Ingestion of Cannabis From Plasma THC and THCCOOH Concentrations (2006) (40)
- Evaluation of a homogenous enzyme immunoassay for the detection of synthetic cannabinoids in urine. (2014) (40)
- Simultaneous quantification of Δ(9)-tetrahydrocannabinol, 11-nor-9-carboxy-tetrahydrocannabinol, cannabidiol and cannabinol in oral fluid by microflow-liquid chromatography-high resolution mass spectrometry. (2013) (39)
- Cannabinoid Markers in Biological Fluids and Tissues: Revealing Intake. (2018) (39)
- Sensitivity, specificity, and efficiency in detecting opiates in oral fluid with the Cozart Opiate Microplate EIA and GC-MS following controlled codeine administration. (2003) (39)
- The Effect of Prenatal Methamphetamine Exposure on Attention as Assessed by Continuous Performance Tests: Results from the Infant Development, Environment, and Lifestyle Study (2013) (39)
- Umbilical cord monitoring of in utero drug exposure to buprenorphine and correlation with maternal dose and neonatal outcomes. (2010) (38)
- Changes in Smoking Patterns During Pregnancy (2013) (38)
- Opioid disposition in human sweat after controlled oral codeine administration. (2006) (38)
- The state of clinical outcome assessments for cannabis use disorder clinical trials: A review and research agenda. (2020) (38)
- Urinary excretion of buprenorphine, norbuprenorphine, buprenorphine-glucuronide, and norbuprenorphine-glucuronide in pregnant women receiving buprenorphine maintenance treatment. (2009) (38)
- Predictors of Inadequate Prenatal Care in Methamphetamine-Using Mothers in New Zealand and the United States (2013) (38)
- Anger, hostility, and aggression as predictors of persistent smoking during pregnancy. (2011) (38)
- Cannabis Edibles: Blood and Oral Fluid Cannabinoid Pharmacokinetics and Evaluation of Oral Fluid Screening Devices for Predicting Δ9-Tetrahydrocannabinol in Blood and Oral Fluid following Cannabis Brownie Administration. (2017) (38)
- Intravenous buprenorphine and norbuprenorphine pharmacokinetics in humans. (2013) (38)
- Mu Opioid Receptor Binding Correlates with Nicotine Dependence and Reward in Smokers (2014) (37)
- Validation of a two-dimensional gas chromatography mass spectrometry method for the simultaneous quantification of cannabidiol, Δ9-tetrahydrocannabinol (THC), 11-hydroxy-THC, and 11-nor-9-carboxy-THC in plasma (2010) (37)
- Distinguishing Intake of New Synthetic Cannabinoids ADB-PINACA and 5F-ADB-PINACA with Human Hepatocyte Metabolites and High-Resolution Mass Spectrometry. (2017) (37)
- Quantitative urine confirmatory testing for synthetic cannabinoids in randomly collected urine specimens. (2015) (37)
- Urinary cannabinoid detection times after controlled oral administration of delta9-tetrahydrocannabinol to humans. (2003) (37)
- 3,4-Methylenedioxypyrovalerone (MDPV) and metabolites quantification in human and rat plasma by liquid chromatography-high resolution mass spectrometry. (2014) (37)
- Determination of methadone, 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine, 2-ethyl-5-methyl-3,3-diphenylpyraline and methadol in meconium by liquid chromatography atmospheric pressure chemical ionization tandem mass spectrometry. (2005) (36)
- Cannabinoids in oral fluid by on-site immunoassay and by GC-MS using two different oral fluid collection devices (2014) (36)
- Impact of enzymatic and alkaline hydrolysis on CBD concentration in urine (2013) (36)
- Rapid quantitative chiral amphetamines liquid chromatography-tandem mass spectrometry: method in plasma and oral fluid with a cost-effective chiral derivatizing reagent. (2014) (36)
- Development and validation of a liquid chromatography-atmospheric pressure chemical ionization-tandem mass spectrometry method for simultaneous analysis of 10 amphetamine-, methamphetamine- and 3,4-methylenedioxymethamphetamine-related (MDMA) analytes in human meconium. (2008) (36)
- Adolescent cortical thickness pre- and post marijuana and alcohol initiation. (2016) (36)
- Effects of oral, smoked, and vaporized cannabis on endocrine pathways related to appetite and metabolism: a randomized, double-blind, placebo-controlled, human laboratory study (2020) (35)
- A preliminary evaluation of the relationship of cannabinoid blood concentrations with the analgesic response to vaporized cannabis (2016) (35)
- Liquid chromatographic/electrospray ionization tandem mass spectrometric analysis for the quantification of buprenorphine, norbuprenorphine, buprenorphine-3-beta-D-glucuronide and norbuprenorphine-3-beta-D-glucuronide in human plasma. (2005) (35)
- Urinary cannabinoid disposition in occasional and frequent smokers: is THC-glucuronide in sequential urine samples a marker of recent use in frequent smokers? (2014) (35)
- Maternal depression and neurobehavior in newborns prenatally exposed to methamphetamine. (2009) (35)
- Acute and residual effects of smoked cannabis: Impact on driving speed and lateral control, heart rate, and self-reported drug effects. (2019) (35)
- Plasma Cannabinoid Pharmacokinetics After Controlled Smoking and Ad libitum Cannabis Smoking in Chronic Frequent Users. (2015) (35)
- Perceived Child Behavior Problems, Parenting Stress, and Maternal Depressive Symptoms Among Prenatal Methamphetamine Users (2012) (35)
- Oral fluid and plasma cannabinoid ratios after around-the-clock controlled oral Δ(9)-tetrahydrocannabinol administration. (2011) (35)
- Prenatal methadone exposure, meconium biomarker concentrations and neonatal abstinence syndrome. (2010) (35)
- Development and validation of a disk solid phase extraction and gas chromatography-mass spectrometry method for MDMA, MDA, HMMA, HMA, MDEA, methamphetamine and amphetamine in sweat. (2007) (35)
- Urinary prevalence, metabolite detection rates, temporal patterns and evaluation of suitable LC-MS/MS targets to document synthetic cannabinoid intake in US military urine specimens (2015) (35)
- First metabolic profile of PV8, a novel synthetic cathinone, in human hepatocytes and urine by high-resolution mass spectrometry (2016) (35)
- THC and CBD concentrations in blood, oral fluid and urine following a single and repeated administration of “light cannabis” (2019) (34)
- Controlled vaporized cannabis, with and without alcohol: subjective effects and oral fluid-blood cannabinoid relationships. (2016) (34)
- Cannabinoid disposition in oral fluid after controlled cannabis smoking in frequent and occasional smokers. (2014) (34)
- Methadone and metabolite urine concentrations in patients maintained on methadone. (2003) (34)
- Validation of a novel method to identify in utero ethanol exposure: simultaneous meconium extraction of fatty acid ethyl esters, ethyl glucuronide, and ethyl sulfate followed by LC-MS/MS quantification (2014) (34)
- Acute effects of intravenous cocaine administration on serum concentrations of ghrelin, amylin, glucagon-like peptide-1, insulin, leptin and peptide YY and relationships with cardiorespiratory and subjective responses. (2017) (33)
- Chronic smoking, but not acute nicotine administration, modulates neural correlates of working memory (2010) (33)
- Morphine and codeine concentrations in human urine following controlled poppy seeds administration of known opiate content. (2014) (33)
- Disposition of MDMA and metabolites in human sweat following controlled MDMA administration. (2009) (33)
- Lowering the federally mandated cannabinoid immunoassay cutoff increases true-positive results. (1994) (32)
- Correspondence Between Perceived Pubertal Development and Hormone Levels in 9-10 Year-Olds From the Adolescent Brain Cognitive Development Study (2021) (32)
- Can oral fluid cannabinoid testing monitor medication compliance and/or cannabis smoking during oral THC and oromucosal Sativex administration? (2013) (32)
- Validation and application of a method for the determination of buprenorphine, norbuprenorphine, and their glucuronide conjugates in human meconium. (2008) (31)
- Urinary Pharmacokinetics of 11-Nor-9-carboxy-Δ9-tetrahydrocannabinol after Controlled Oral Δ9-Tetrahydrocannabinol Administration (2004) (31)
- Cozart RapiScan Oral Fluid Drug Testing System: an evaluation of sensitivity, specificity, and efficiency for cocaine detection compared with ELISA and GC-MS following controlled cocaine administration. (2003) (31)
- Prenatal methamphetamine exposure and neonatal and infant neurobehavioral outcome: results from the IDEAL study. (2014) (31)
- Development and validation of a liquid chromatography mass spectrometry assay for the simultaneous quantification of methadone, cocaine, opiates and metabolites in human umbilical cord. (2009) (30)
- Strategies for quitting among non-treatment-seeking marijuana smokers. (2005) (30)
- Performance characteristics of an ELISA screening assay for urinary synthetic cannabinoids. (2015) (30)
- Two-dimensional gas chromatography/electron-impact mass spectrometry with cryofocusing for simultaneous quantification of MDMA, MDA, HMMA, HMA, and MDEA in human plasma. (2008) (30)
- Pharmacokinetic, behavioral, and brain activity effects of Δ9-tetrahydrocannabinol in adolescent male and female rats (2020) (30)
- Optimization and validation of a liquid chromatography-tandem mass spectrometry method for the simultaneous quantification of nicotine, cotinine, trans-3′-hydroxycotinine and norcotinine in human oral fluid (2009) (30)
- Δ9-Tetrahydrocannabinol, 11-Hydroxy-Δ9-Tetrahydrocannabinol and 11-Nor-9-Carboxy-Δ9-Tetrahydrocannabinol in Human Plasma After Controlled Oral Administration of Cannabinoids (2006) (30)
- Comparative Pharmacokinetics of Δ9-Tetrahydrocannabinol in Adolescent and Adult Male Mice (2020) (30)
- Meconium nicotine and metabolites by liquid chromatography-tandem mass spectrometry: differentiation of passive and nonexposure and correlation with neonatal outcome measures. (2008) (30)
- In vitro and in vivo human metabolism of a new synthetic cannabinoid NM-2201 (CBL-2201) (2016) (30)
- Metabolic characterization of AH-7921, a synthetic opioid designer drug: in vitro metabolic stability assessment and metabolite identification, evaluation of in silico prediction, and in vivo confirmation. (2016) (30)
- School-Aged Outcomes following Prenatal Methamphetamine Exposure: 7.5-Year Follow-Up from the Infant Development, Environment, and Lifestyle Study. (2016) (30)
- Population-Based Input Function Modeling for [18F]FMPEP-d 2, an Inverse Agonist Radioligand for Cannabinoid CB1 Receptors: Validation in Clinical Studies (2013) (29)
- Stereoselective urinary MDMA (ecstasy) and metabolites excretion kinetics following controlled MDMA administration to humans. (2012) (29)
- Nonlinear Pharmacokinetics of (±)3,4-Methylenedioxymethamphetamine (MDMA) and Its Pharmacodynamic Consequences in the Rat (2014) (29)
- Validity testing of the accuPINCH THC test. (1995) (29)
- Development and validation of LC-HRMS and GC-NICI-MS methods for stereoselective determination of MDMA and its phase I and II metabolites in human urine. (2011) (29)
- Direct Comparison of (±) 3,4-Methylenedioxymethamphetamine (“Ecstasy”) Disposition and Metabolism in Squirrel Monkeys and Humans (2009) (29)
- Pharmacokinetics of THC in Inhaled and Oral Preparations (1999) (29)
- Around-the-clock oral THC effects on sleep in male chronic daily cannabis smokers. (2013) (28)
- Extended plasma cannabinoid excretion in chronic frequent cannabis smokers during sustained abstinence and correlation with psychomotor performance. (2016) (28)
- Sativex Associated With Behavioral-Relapse Prevention Strategy as Treatment for Cannabis Dependence: A Case Series (2016) (28)
- Executive Summary: American Association of Clinical Chemistry Laboratory Medicine Practice Guideline-Using Clinical Laboratory Tests to Monitor Drug Therapy in Pain Management Patients. (2018) (28)
- Evaluation of divided attention psychophysical task performance and effects on pupil sizes following smoked, vaporized and oral cannabis administration (2017) (28)
- The Effects of Prenatal Methamphetamine Exposure on Childhood Growth Patterns from Birth to 3 Years of Age (2011) (28)
- Urinary excretion kinetics of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) and its phase I and phase II metabolites in humans following controlled MDMA administration. (2011) (28)
- A rapid reusable fiber optic biosensor for detecting cocaine metabolites in urine. (1999) (28)
- Impact of Novel Psychoactive Substances on Clinical and Forensic Toxicology and Global Public Health. (2017) (28)
- A review of synthetic cathinone-related fatalities from 2017 to 2020. (2020) (27)
- Screening of 104 New Psychoactive Substances (NPS) and Other Drugs of Abuse in Oral Fluid by LC-MS-MS. (2020) (27)
- Sensitive gas chromatography-mass spectrometry method for simultaneous measurement of MDEA, MDMA, and metabolites HMA, MDA, and HMMA in human urine. (2006) (27)
- In Vitro Metabolite Profiling of ADB-FUBINACA, A New Synthetic Cannabinoid. (2017) (27)
- Monitoring Pregnant Women's Illicit Opiate and Cocaine Use With Sweat Testing (2010) (27)
- MATERNAL DEPRESSION AND PRENATAL EXPOSURE TO METHAMPHETAMINE: NEURODEVELOPMENTAL FINDINGS FROM THE INFANT DEVELOPMENT, ENVIRONMENT, AND LIFESTYLE (IDEAL) STUDY (2012) (27)
- Cannabinoids and metabolites in expectorated oral fluid after 8 days of controlled around-the-clock oral THC administration (2011) (26)
- Drug exposure during pregnancy: analytical methods and toxicological findings. (2018) (26)
- Simultaneous quantification of nicotine, opioids, cocaine, and metabolites in human fetal postmortem brain by liquid chromatography tandem mass spectrometry (2009) (26)
- Effect of hydrolysis on identifying prenatal cannabis exposure (2010) (26)
- Identifying and Quantifying Cannabinoids in Biological Matrices in the Medical and Legal Cannabis Era. (2020) (26)
- Simultaneous quantification of buprenorphine, norbuprenorphine, buprenorphine-glucuronide and norbuprenorphine-glucuronide in human umbilical cord by liquid chromatography tandem mass spectrometry. (2009) (26)
- Judicial acceptance of hair tests for substances of abuse in the United States courts: scientific, forensic, and ethical aspects. (1996) (26)
- Estimating the time of last cannabis use from plasma delta9-tetrahydrocannabinol and 11-nor-9-carboxy-delta9-tetrahydrocannabinol concentrations. (2005) (25)
- Oral fluid/plasma cannabinoid ratios following controlled oral THC and smoked cannabis administration (2013) (25)
- Smoking in Pregnancy and Fetal Growth: The Case for More Intensive Assessment (2017) (25)
- Urinary excretion of ecgonine and five other cocaine metabolites following controlled oral, intravenous, intranasal, and smoked administration of cocaine. (2010) (25)
- Long-term stability of cannabinoids in oral fluid after controlled cannabis administration. (2017) (25)
- A validated liquid chromatography-atmospheric pressure chemical ionization-tandem mass spectrometric method for the quantification of methadone, 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP), and 2-Ethyl-5-methyl-3,3-diphenylpyroline (EMDP) in human breast milk. (2007) (25)
- Simultaneous quantification of nicotine, cotinine, trans-3'-hydroxycotinine, norcotinine and mecamylamine in human urine by liquid chromatography-tandem mass spectrometry. (2012) (25)
- Validation of a LC-APCI-MS/MS method for quantification of methadone, 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP) and 2-ethyl-5-methyl-3,3-diphenylpyraline (EMDP) in infant plasma following protein precipitation. (2007) (24)
- Human Cannabinoid Pharmacokinetics and Interpretation of Cannabinoid Concentrations in Biological Fluids and Tissues (2007) (24)
- Validity testing of the EZ-SCREEN cannabinoid test. (1993) (24)
- Simultaneous GC-EI-MS determination of Delta9-tetrahydrocannabinol, 11-hydroxy-Delta9-tetrahydrocannabinol, and 11-nor-9-carboxy-Delta9-tetrahydrocannabinol in human urine following tandem enzyme-alkaline hydrolysis. (2007) (24)
- Simultaneous liquid chromatography-mass spectrometry quantification of urinary opiates, cocaine, and metabolites in opiate-dependent pregnant women in methadone-maintenance treatment. (2010) (24)
- Maternal Buprenorphine Maintenance and Lactation (2016) (24)
- Modern analytical technologies for the detection of drug abuse and doping. (2006) (24)
- Modelling foetal exposure to maternal smoking using hepatoblasts from pluripotent stem cells (2017) (24)
- Buprenorphine and norbuprenorphine in hair of pregnant women and their infants after controlled buprenorphine administration. (2007) (24)
- Prenatal tobacco exposure and infant stress reactivity: role of child sex and maternal behavior. (2015) (24)
- Impact of oral fluid collection device on cannabinoid stability following smoked cannabis. (2015) (24)
- Sensitivity and specificity of the Cozart microplate EIA cocaine oral fluid at proposed screening and confirmation cutoffs. (2003) (24)
- Rimonabant effects on anxiety induced by simulated public speaking in healthy humans: a preliminary report (2014) (24)
- Delta(9)-tetrahydrocannabinol, 11-hydroxy-delta(9)-tetrahydrocannabinol and 11-nor-9-carboxy-delta(9)-tetrahydrocannabinol in human plasma after controlled oral administration of cannabinoids. (2006) (23)
- Confirmatory analysis of buprenorphine, norbuprenorphine, and glucuronide metabolites in plasma by LCMSMS. Application to umbilical cord plasma from buprenorphine-maintained pregnant women. (2010) (23)
- Validation of a liquid chromatography tandem mass spectrometry (LC-MS/MS) method to detect cannabinoids in whole blood and breath (2019) (23)
- Pharmacokinetic Profiles and Pharmacodynamic Effects for Methylone and Its Metabolites in Rats (2017) (23)
- Cocaine and metabolite concentrations in DBS and venous blood after controlled intravenous cocaine administration. (2015) (23)
- Prenatal exposure to tobacco and cannabis: Effects on autonomic and emotion regulation. (2018) (23)
- A validated positive chemical ionization GC/MS method for the identification and quantification of amphetamine, opiates, cocaine, and metabolites in human postmortem brain. (2006) (23)
- Simultaneous quantification of methamphetamine, cocaine, codeine, and metabolites in skin by positive chemical ionization gas chromatography-mass spectrometry. (2006) (23)
- Metabolism of RCS-8, a synthetic cannabinoid with cyclohexyl structure, in human hepatocytes by high-resolution MS. (2014) (22)
- Recent Marijuana Blunt Smoking Impacts Carbon Monoxide as a Measure of Adolescent Tobacco Abstinence (2005) (22)
- Oral fluid cocaine and benzoylecgonine concentrations following controlled intravenous cocaine administration. (2016) (22)
- Strategies to distinguish new synthetic cannabinoid FUBIMINA (BIM-2201) intake from its isomer THJ-2201: metabolism of FUBIMINA in human hepatocytes (2016) (22)
- Commonly Practiced Quality Control and Quality Assurance Procedures for Gas Chromatography-Mass Spectrometry Analysis in Forensic Urine Drug-Testing Laboratories. (1997) (22)
- Validation of an enzyme immunoassay for detection and semiquantification of cannabinoids in oral fluid. (2010) (22)
- Optimization of recombinant β-glucuronidase hydrolysis and quantification of eight urinary cannabinoids and metabolites by liquid chromatography tandem mass spectrometry. (2018) (22)
- In vitro stability of free and glucuronidated cannabinoids in urine following controlled smoked cannabis (2013) (22)
- One Hundred False-Positive Amphetamine Specimens Characterized by Liquid Chromatography Time-of-Flight Mass Spectrometry. (2015) (21)
- Toxicology and Analysis of Psychoactive Tryptamines (2020) (21)
- Quantification of cocaine and metabolites in exhaled breath by liquid chromatography-high-resolution mass spectrometry following controlled administration of intravenous cocaine (2014) (21)
- Designer Benzodiazepines: A Review of Toxicology and Public Health Risks (2021) (21)
- Selection and optimization of hydrolysis conditions for the quantification of urinary metabolites of MDMA. (2006) (21)
- Antagonist-Elicited Cannabis Withdrawal in Humans (2011) (21)
- 11-Nor-9-carboxy-∆9-tetrahydrocannabinol quantification in human oral fluid by liquid chromatography–tandem mass spectrometry (2013) (21)
- Changes in marijuana use symptoms and emotional functioning over 28-days of monitored abstinence in adolescent marijuana users (2017) (21)
- Decreased Cannabinoid CB1 Receptors in Male Tobacco Smokers Examined With Positron Emission Tomography (2018) (20)
- Biochip array technology immunoassay performance and quantitative confirmation of designer piperazines for urine workplace drug testing (2015) (20)
- 3,4-Methylenedioxymethamphetamine (MDMA) and metabolites disposition in blood and plasma following controlled oral administration (2013) (20)
- A concise methodology for the synthesis of (-)-Δ9-tetrahydrocannabinol and (-)-Δ9-tetrahydrocannabivarin metabolites and their regiospecifically deuterated analogs (2007) (20)
- Oral fluid and plasma 3,4-methylenedioxymethamphetamine (MDMA) and metabolite correlation after controlled oral MDMA administration (2013) (20)
- MDMA and Metabolite Disposition in Expectorated Oral Fluid After Controlled Oral MDMA Administration (2011) (20)
- Therapeutic potential and safety considerations for the clinical use of synthetic cannabinoids (2020) (20)
- Deterring driving under the influence of cannabis. (2015) (20)
- Cannabis-impaired driving: a public health and safety concern. (2015) (19)
- Cannabis Use and Car Crashes: A Review (2021) (19)
- Plasma Cannabinoid Concentrations During Dronabinol Pharmacotherapy for Cannabis Dependence (2014) (19)
- Novel Biomarkers of Prenatal Methamphetamine Exposure in Human Meconium (2009) (18)
- Simultaneous quantification of buprenorphine, naloxone and phase I and II metabolites in plasma and breastmilk by liquid chromatography-tandem mass spectrometry. (2016) (18)
- Simultaneous quantification of buprenorphine, norbuprenorphine, buprenorphine glucuronide, and norbuprenorphine glucuronide in human placenta by liquid chromatography mass spectrometry (2009) (18)
- Identification of New Synthetic Cannabinoid ADB-CHMINACA (MAB-CHMINACA) Metabolites in Human Hepatocytes (2017) (18)
- Simultaneous liquid chromatographic-electrospray ionization mass spectrometric quantification of 3,4-methylenedioxymethamphetamine (MDMA, Ecstasy) and its metabolites 3,4-dihydroxymethamphetamine, 4-hydroxy-3-methoxymethamphetamine and 3,4-methylenedioxyamphetamine in squirrel monkey and human plasm (2009) (18)
- Validation of an ELISA Synthetic Cannabinoids Urine Assay (2015) (18)
- Cortisol reactivity in two-year-old children prenatally exposed to methamphetamine. (2013) (18)
- Hydrolysis of 3,4-methylenedioxymethamphetamine (MDMA) metabolite conjugates in human, squirrel monkey, and rat plasma (2009) (18)
- Driving Performance and Cannabis Users’ Perception of Safety (2022) (18)
- Metabolite profiling of RCS-4, a novel synthetic cannabinoid designer drug, using human hepatocyte metabolism and TOF-MS. (2014) (17)
- Meconium Tenofovir Concentrations and Growth and Bone Outcomes in Prenatally Tenofovir Exposed HIV-Uninfected Children (2015) (17)
- Development and validation of the first liquid chromatography-tandem mass spectrometry assay for simultaneous quantification of multiple antiretrovirals in meconium. (2013) (17)
- A validated gas chromatographic-electron impact ionization mass spectrometric method for methamphetamine, methylenedioxymethamphetamine (MDMA), and metabolites in mouse plasma and brain. (2008) (17)
- CB1 – Cannabinoid Receptor Antagonist Effects on Cortisol in Cannabis-Dependent Men (2012) (17)
- Pharmacodynamic effects and relationships to plasma and oral fluid pharmacokinetics after intravenous cocaine administration. (2016) (17)
- Assessing In Utero Exposure to Cannabis and Cocaine (2006) (17)
- Additive drug-specific and sex-specific risks associated with co-use of marijuana and tobacco during pregnancy: Evidence from 3 recent developmental cohorts (2003-2015). (2018) (16)
- Risk of Neurobehavioral Disinhibition in Prenatal Methamphetamine–Exposed Young Children With Positive Hair Toxicology Results (2014) (16)
- Recent Self-Reported Cannabis Use Is Associated With the Biometrics of Delta-9-Tetrahydrocannabinol. (2018) (16)
- Cross-national Comparison of Prenatal Methamphetamine Exposure on Infant and Early Child Physical Growth: A Natural Experiment (2014) (16)
- Priority Considerations for Medicinal Cannabis-Related Research. (2019) (16)
- Methadone and Metabolites in Hair of Methadone-Assisted Pregnant Women and Their Infants (2012) (16)
- Method validation of the biochip array technology for synthetic cannabinoids detection in urine. (2014) (16)
- Oral fluid cannabinoids in chronic frequent cannabis smokers during ad libitum cannabis smoking. (2015) (15)
- Oral fluid cannabinoids in chronic cannabis smokers during oral δ9-tetrahydrocannabinol therapy and smoked cannabis challenge. (2013) (15)
- Acute and residual mood and cognitive performance of young adults following smoked cannabis (2020) (15)
- Development and validation of a liquid chromatography–tandem mass spectrometry assay for the simultaneous quantification of buprenorphine, norbuprenorphine, and metabolites in human urine (2008) (15)
- A new ultraperformance-tandem mass spectrometry oral fluid assay for 29 illicit drugs and medications. (2009) (15)
- Prenatal tobacco and marijuana co-use: Impact on newborn neurobehavior. (2018) (15)
- Fatty Acid Amide Hydrolase Binding in Brain of Cannabis Users : Imaging With the Novel Radiotracer [ 11 C ] CURB (2016) (14)
- Synthetic cannabinoid BB‐22 (QUCHIC): Human hepatocytes metabolism with liquid chromatography‐high resolution mass spectrometry detection (2018) (14)
- Oral Fluid Nicotine Markers to Assess Smoking Status and Recency of Use (2011) (14)
- CLINICAL STUDY: Postmortem diagnosis and toxicological validation of illicit substance use (2008) (14)
- Prenatal Tobacco and Cannabis Exposure: Associations with Cortisol Reactivity in Early School Age Children (2020) (14)
- Testing Unconventional Matrices to Monitor for Prenatal Exposure to Heroin, Cocaine, Amphetamines, Synthetic Cathinones, and Synthetic Opioids. (2019) (14)
- Identifying Methamphetamine Exposure in Children (2013) (14)
- Detection of opiate use in a methadone maintenance treatment population with the CEDIA 6-acetylmorphine and CEDIA DAU opiate assays. (2001) (14)
- Reports of Adverse Events Associated with Use of Novel Psychoactive Substances, 2017–2020: A Review (2022) (13)
- Cannabinoid disposition in oral fluid after controlled vaporizer administration with and without alcohol (2015) (13)
- Urinary pharmacokinetics of 11-nor-9-carboxy-delta9-tetrahydrocannabinol after controlled oral delta9-tetrahydrocannabinol administration. (2004) (13)
- Methamphetamine and amphetamine isomer concentrations in human urine following controlled Vicks VapoInhaler administration. (2014) (13)
- Quantification of 11-Nor-9-Carboxy-&Dgr;9-Tetrahydrocannabinol in Human Oral Fluid by Gas Chromatography–Tandem Mass Spectrometry (2014) (13)
- Cocaine and benzoylecgonine oral fluid on-site screening and confirmation. (2016) (13)
- Oral fluid with three modes of collection and plasma methamphetamine and amphetamine enantiomer concentrations after controlled intranasal l-methamphetamine administration. (2015) (13)
- Development and Validation of an LC-MS-MS Method for the Detection of 40 Benzodiazepines and Three Z-Drugs in Blood and Urine by Solid-Phase Extraction. (2020) (13)
- New meconium biomarkers of prenatal methamphetamine exposure increase identification of affected neonates. (2010) (13)
- Morphine and codeine in oral fluid after controlled poppy seed administration. (2015) (13)
- Prenatal Risk and Infant Regulation: Indirect Pathways via Fetal Growth and Maternal Prenatal Stress and Anger. (2018) (12)
- The acute effect of cannabis on plasma, liver and brain ammonia dynamics, a translational study (2017) (12)
- Usefulness of salivary trans-3'-hydroxycotinine concentration and trans-3'-hydroxycotinine/cotinine ratio as biomarkers of cigarette smoke in pregnant women. (2005) (12)
- Excretion of Methadone in Sweat of Pregnant Women Throughout Gestation After Controlled Methadone Administration (2010) (12)
- Urinary Excretion of 11-Nor-9-Carboxy-Δ9-Tetrahydrocannabinol in a Pregnant Woman Following Heavy, Chronic Cannabis Use (2009) (12)
- Piezoresistive Microcantilevers-Based Cocaine Biosensors (2012) (12)
- Monitoring Perinatal Exposure to Cannabis and Synthetic Cannabinoids. (2020) (12)
- Pharmacodynamic Effects, Pharmacokinetics, and Metabolism of the Synthetic Cannabinoid AM-2201 in Male Rats (2018) (11)
- Excretion of Delta9-tetrahydrocannabinol in sweat. (2008) (11)
- Developmental effects of maternal smoking during pregnancy on the human frontal cortex transcriptome (2017) (11)
- Physiological regulation in cigarette exposed infants: an examination of potential moderators. (2011) (11)
- Correlation of creatinine- and specific gravity-normalized free and glucuronidated urine cannabinoid concentrations following smoked, vaporized, and oral cannabis in frequent and occasional cannabis users. (2019) (11)
- Miniaturized extraction method for analysis of synthetic opioids in urine by microextraction with packed sorbent and liquid chromatography-tandem mass spectrometry. (2020) (11)
- Extended Detection of Amphetamine and Methamphetamine in Oral Fluid (2016) (11)
- (±)-3,4-methylenedioxymethamphetamine and metabolite disposition in plasma and striatum of wild-type and multidrug resistance protein 1a knock-out mice. (2011) (11)
- In Vitro Metabolite Profiling of ADB-FUBINACA, A New Synthetic Cannabinoid (2017) (11)
- Human Hepatocyte Metabolism of Novel Synthetic Cannabinoids MN-18 and Its 5-Fluoro Analog 5F-MN-18. (2017) (10)
- Development and Validation of a Method for Quantification of 28 Psychotropic Drugs in Postmortem Blood Samples by Modified Micro-QuEChERS and LC-MS-MS. (2020) (10)
- Quantification of methylone and metabolites in rat and human plasma by liquid chromatography-tandem mass spectrometry (2015) (10)
- Simultaneous plasma and oral fluid morphine and codeine concentrations after controlled administration of poppy seeds with known opiate content (2015) (10)
- THC and CBD blood and brain concentrations following daily administration to adolescent primates. (2020) (10)
- Metabolism of the new synthetic cannabinoid EG-018 in human hepatocytes by high-resolution mass spectrometry (2018) (10)
- Methadone disposition in oral fluid during pharmacotherapy for opioid-dependence. (2011) (10)
- On-site oral fluid Δ9-tetrahydrocannabinol (THC) screening after controlled smoked, vaporized, and oral cannabis administration (2016) (10)
- Cannabinoid Pharmacokinetics and Disposition in Alternative Matrices (2014) (10)
- Biomarkers of Recent Cannabis Use in Blood, Oral Fluid and Breath. (2021) (10)
- Combined effect of alcohol and cannabis on simulated driving (2021) (9)
- Meconium Atazanavir Concentrations and Early Language Outcomes in HIV-Exposed Uninfected Infants With Prenatal Atazanavir Exposure (2015) (9)
- In vitro assessment of the cytotoxic, genotoxic and oxidative stress effects of the synthetic cannabinoid JWH-018 in human SH-SY5Y neuronal cells. (2020) (9)
- Monitoring Prenatal Exposure to Buprenorphine and Methadone. (2020) (9)
- Naloxone and Metabolites Quantification in Cord Blood of Prenatally Exposed Newborns and Correlations with Maternal Concentrations (2016) (9)
- Recommendations for Toxicological Investigation of Drug-Impaired Driving and Motor Vehicle Fatalities—2021 Update (2021) (9)
- xtended urinary 9-tetrahydrocannabinol excretion in chronic cannabis sers precludes use as a biomarker of new drug exposure oss (2009) (9)
- A comparison of Roche Kinetic Interaction of Microparticles in Solution (KIMS) assay for cannabinoids and GC-MS analysis for 11-nor-9-carboxy-delta9-tetrahydrocannabinol. (2001) (9)
- Co-use of tobacco and marijuana during pregnancy: Pathways to externalizing behavior problems in early childhood. (2018) (9)
- Preliminary data on the potential for unintentional anti-doping rule violations by permitted CBD use. (2020) (8)
- Impact of cannabis and low alcohol concentration on divided attention tasks during driving (2020) (8)
- NBOMe instability in whole blood (2018) (8)
- LC–ESI-MS/MS analysis for the quantification of morphine, codeine, morphine-3-β-D-glucuronide, morphine-6-β-D-glucuronide, and codeine-6-β-D-glucuronide in human urine J. Mass Spectrom. 2005; 40: 1412–1416 (2006) (8)
- Prenatal exposure to tobacco and marijuana and child autonomic regulation and reactivity: An analysis of indirect pathways via maternal psychopathology and parenting. (2019) (8)
- Pyrrolidinyl Synthetic Cathinones α-PHP and 4F-α-PVP Metabolite Profiling Using Human Hepatocyte Incubations (2020) (8)
- Effects of the Psychedelic Amphetamine MDA (3,4-Methylenedioxyamphetamine) in Healthy Volunteers (2019) (8)
- Tobacco Exposure and Conditional Weight-for-Length Gain by 2 Years of Age (2017) (8)
- In vitro metabolism of new synthetic cannabinoid SDB-006 in human hepatocytes by high-resolution mass spectrometry (2017) (7)
- Effects of fetal tobacco exposure on focused attention in infancy. (2016) (7)
- Kratom Abuse Potential 2021: An Updated Eight Factor Analysis (2022) (7)
- Re: "trends in alcohol and other drugs detected in fatally injured drivers in the United States, 1999-2010". (2014) (7)
- LC-ESI-MS/MS analysis for the quantification of morphine, codeine, morphine-3-beta-D-glucuronide, morphine-6-beta-D-glucuronide, and codeine-6-beta-D-glucuronide in human urine. (2005) (7)
- Free and Glucuronide Urine Cannabinoids after Controlled Smoked, Vaporized, and Oral Cannabis Administration in Frequent and Occasional Cannabis Users. (2020) (7)
- Prevalence of new psychoactive substances (NPS) in Brazil based on oral fluid analysis of samples collected at electronic music festivals and parties. (2021) (7)
- In vitro stability of free and glucuronidated cannabinoids in blood and plasma collected in plastic gray-top sodium fluoride tubes following controlled smoked cannabis (2015) (7)
- Antiretroviral Drugs in Meconium: Detection for Different Gestational Periods of Exposure. (2015) (7)
- Prenatal tobacco and marijuana co-use: Sex-specific influences on infant cortisol stress response. (2020) (7)
- Monitoring the effects of perinatal cannabis and synthetic cannabinoid exposure. (2019) (6)
- Separate and combined effects of alcohol and cannabis on mood, subjective experience, cognition and psychomotor performance: A randomized trial (2022) (6)
- Blood and Oral Fluid Cannabinoid Profiles of Frequent and Occasional Cannabis Smokers. (2021) (6)
- Quantification of ethyl glucuronide, ethyl sulfate, nicotine, and its metabolites in human fetal liver and placenta (2017) (6)
- Controlled Drug Administration Studies of High-Dose Buprenorphine in Humans (2002) (6)
- Tobacco exposure and maternal psychopathology: Impact on toddler problem behavior. (2016) (6)
- Simultaneous determination of delta9-tetrahydrocannabinol and 11-nor-9-carboxy-delta9-tetrahydrocannabinol in human plasma by solid-phase extraction and gas chromatography-negative ion chemical ionization-mass spectrometry. (2001) (6)
- Urine Mescaline Screening With a Biochip Array Immunoassay and Quantification by Gas Chromatography–Mass Spectrometry (2015) (6)
- Short communication: Urinary excretion of 11-nor-9-carboxy-Delta(9)-tetrahydrocannabinol in a pregnant woman following heavy, chronic cannabis use. (2009) (6)
- Physiological Regulation at 9 Months of Age in Infants Prenatally Exposed to Cigarettes. (2013) (5)
- Quantification of [1-(5-fluoropentyl)-1H-indol-3-yl](naphthalene-1-yl)methanone (AM-2201) and 13 metabolites in human and rat plasma by liquid chromatography-tandem mass spectrometry. (2016) (5)
- Mice Lacking Multidrug Resistance Protein 1a Show Altered Dopaminergic Responses to Methylenedioxymethamphetamine (MDMA) in Striatum (2010) (5)
- Acute Effects of Cannabis on Young Drivers' Performance of Driving Related Skills (2015) (5)
- Urinary Excretion of Commonly Abused Drugs Following Uncommon Means of Administration. (1989) (5)
- Sex differences in the acute pharmacological and subjective effects of smoked cannabis combined with alcohol in young adults. (2021) (5)
- Simultaneous determination of buprenorphine, norbuprenorphine, and buprenorphine glucuronide in plasma by LC-MS-MS. (2001) (5)
- Comparative Neuropharmacology and Pharmacokinetics of Methamphetamine and Its Thiophene Analog Methiopropamine in Rodents (2021) (5)
- Identification and quantification of cannabinoids in postmortem fluids and tissues by liquid chromatography-tandem mass spectrometry. (2021) (5)
- Identification of ∆9-tetrahydrocannabinol (THC) impairment using functional brain imaging (2022) (5)
- Population pharmacokinetic modeling of plasma Δ9‐tetrahydrocannabinol and an active and inactive metabolite following controlled smoked cannabis administration (2019) (5)
- Comparison of (+)- and (−)-Naloxone on the Acute Psychomotor-Stimulating Effects of Heroin, 6-Acetylmorphine, and Morphine in Mice (2016) (4)
- Behavior Problems During Early Childhood in Children With Prenatal Methamphetamine Exposure (2020) (4)
- Psychiatric symptom differences in people with schizophrenia associated with substantial lifetime substance use but no current substance use disorder (2013) (4)
- Pharmacokinetics and Pharmacodynamics of Drugs Abused in Driving (2009) (4)
- Methylone and MDMA Pharmacokinetics Following Controlled Administration in Humans (2022) (4)
- Delayed emergence of methamphetamine's enhanced cardiovascular effects in nonhuman primates during protracted methamphetamine abstinence. (2016) (4)
- Methadone Maintenance and Breastfeeding in the Neonatal Period: In Reply (2008) (4)
- Subtherapeutic Acetazolamide Doses as a Noninvasive Method for Assessing Medication Adherence (2020) (4)
- Preliminary Evidence for Cannabis and Nicotine Urinary Metabolites as Predictors of Verbal Memory Performance and Learning Among Young Adults (2021) (3)
- Interpreting Alternative Matrix Test Results (2007) (3)
- Substance use onset in high-risk 9-13 year-olds in the ABCD study. (2021) (3)
- Measuring Within-Individual Cannabis Reduction in Clinical Trials: a Review of the Methodological Challenges (2019) (3)
- Evaluation of the on-site Draeger DrugTest 5000 in occasional and chronic frequent smokers following controlled cannabis smoking (2013) (3)
- Loweringthe FederallyMandatedCannabinoidImmunoassay CutoffIncreases True-PositiveResults (1994) (3)
- Human MDMA (Ecstasy) and Phase I and Phase II Metabolite Urinary Excretion Kinetics Following Controlled MDMA Administration (2011) (3)
- Chronic heavy cannabis use downregulates brain cannabinoid CB1 receptors in humans (2010) (2)
- Cannabinoid distribution in fatally-injured pilots' postmortem fluids and tissues. (2021) (2)
- Effects of the cannabinoid-1 receptor antagonist/inverse agonist rimonabant on satiety signaling in overweight people with schizophrenia: a randomized, double-blind, pilot study. (2013) (2)
- Do consecutive urine catches differ in marijuana metabolite concentration? (1993) (2)
- Interpreting oral fluid drug results in prisoners: monitoring current drug intake and detection times for drugs self-administered prior to detention (2018) (2)
- Human Hepatocyte 4-Acetoxy-N,N-Diisopropyltryptamine Metabolite Profiling by Reversed-Phase Liquid Chromatography Coupled with High-Resolution Tandem Mass Spectrometry (2022) (2)
- Urinary Acrylonitrile Metabolite Concentrations Before and after Smoked, Vaporized, and Oral Cannabis in Frequent and Occasional Cannabis Users (2020) (2)
- Technical and Legal Aspects of Drugs of Abuse Testing in Hair (2020) (2)
- Nicotinic receptor modulation of the default mode network (2020) (2)
- Concordance between substance use self-report and hair analysis in community-based adolescents (2023) (2)
- Review of: Medical Toxicology of Natural Substances: Foods, Fungi, Medicinal Herbs, Plants, and Venomous Animals (2009) (2)
- Influence of personality on acute smoked cannabis effects on simulated driving. (2021) (2)
- The effect of prenatal adversity on externalizing behaviors at 24 months of age in a high-risk sample: Maternal sensitivity as a moderator. (2020) (2)
- Review for "Maternal‐fetal transmission of delta‐9‐tetrahydrocannabinol (THC) and its metabolites following inhalation and injection exposure during pregnancy in rats" (2021) (1)
- Signal-Averaged Electrocardiogram in Physically Healthy, Chronic 3,4-Methylenedioxymethamphetamine (MDMA) Users (2008) (1)
- Respiratory effects of oral mitragynine and oxycodone in a rodent model (2022) (1)
- Changes in marijuana use symptoms and emotional functioning over 28-days of monitored abstinence in adolescent marijuana users (2017) (1)
- "Recent challenges and trends in forensic analysis: Δ9-THC isomers pharmacology, toxicology and analysis". (2022) (1)
- 4-Hydroxy-N,N-methylpropyltryptamine (4-OH-MPT) in vitro human metabolism (2022) (1)
- A Sensitive Ultrahigh-Performance Liquid Chromatography/Tandem Mass Spectrometry Method for the Simultaneous Analysis of Phytocannabinoids and Endocannabinoids in Plasma and Brain. (2022) (1)
- Preliminary data on the potential for unintentional antidoping rule violations by permitted cannabidiol (CBD) use (2021) (1)
- Effects of fixed or self-titrated dosages of Sativex on cannabis users (2015) (1)
- Reprint of "Adolescent cortical thickness pre- and post marijuana and alcohol initiation". (2016) (1)
- Altering the landscape for women in clinical chemistry: perspectives from multigenerational leaders. (2012) (1)
- Simple Stimulus Detection: An fMRI Study Performance Effects of Nicotine during Selective Attention, Divided Attention, and (2009) (1)
- Metabolism of Carfentanil, an Ultra-Potent Opioid, in Human Liver Microsomes and Human Hepatocytes by High-Resolution Mass Spectrometry (2016) (1)
- Risk of unintentional antidoping rule violations by consumption of hemp products. (2022) (1)
- Decreased brain cannabinoid CB1 receptor binding in tobacco smokers examined with positron emission tomography (2014) (1)
- Physiological reactivity during object manipulation among cigarette-exposed infants at 9 months of age. (2015) (1)
- Intravenous buprenorphine: Effects of 2 to 16 mg doses in nondependent opioid abusers (2001) (1)
- Comparative Pharmacokinetics of D 9 -Tetrahydrocannabinol in Adolescent and Adult Male Mice s (2020) (0)
- Nicotinic receptor modulation of the default mode network (2020) (0)
- Prenatal tobacco and cannabis co‐exposure and offspring obesity development from birth to mid‐childhood (2023) (0)
- Erratum to: Modelling foetal exposure to maternal smoking using hepatoblasts from pluripotent stem cells (2017) (0)
- Identification of New Synthetic Cannabinoid ADB-CHMINACA (MAB-CHMINACA) Metabolites in Human Hepatocytes (2017) (0)
- Molecular Insights and Clinical Outcomes of Drugs of Abuse Adulteration: New Trends and New Psychoactive Substances (2022) (0)
- Eclipse can deliver crack cocaine. (2002) (0)
- 120: Quantification of naloxone and metabolites in cord blood of prenatally-exposed newborns and correlations with maternal concentrations (2016) (0)
- Review for "Maternal‐fetal transmission of delta‐9‐tetrahydrocannabinol (THC) and its metabolites following inhalation and injection exposure during pregnancy in rats" (2021) (0)
- Preliminary report on the residual effects of cannabis on young drivers’ performance of driving-related skills (2015) (0)
- The importsnce f cannabis pharmacokinetics to the interpretation of toxicological results (2007) (0)
- Perceived Child Behavior Problems, Parenting Stress, and Maternal Depressive Symptoms Among Prenatal Methamphetamine Users (2012) (0)
- Biomarkers of 4-hydroxy-N,N-methylpropyltryptamine (4-OH-MPT) intake identified from human hepatocyte incubations (2022) (0)
- Fortieth Anniversary Annual Meeting of the Developmental Neurotoxicology Society Held in Conjunction with the 56 th Annual Meeting of the Teratology Society Grand (2016) (0)
- Urinary Clearance of 11-Nor-9-Carboxy-Δ9 -Tetrahydrocannabinol (THCCOOH): A Detailed Pharmacokinetic Analysis. (2022) (0)
- Cannabidiol, ∆9-tetrahydrocannabinol, and metabolites in human blood by volumetric absorptive microsampling and LC-MS/MS following controlled administration in epilepsy patients (2022) (0)
- Correction to: Identification of ∆9-tetrahydrocannabinol (THC) impairment using functional brain imaging (2022) (0)
- In utero exposure to cigarette smoke and NAFLD pathways: Sex and age specific effects in the human fetus (2018) (0)
- Using Population Pharmacokinetic Modeling to Estimate Exposure to Δ9-tetrahydrocannabinol in an Observational Study of Cannabis Smokers in Colorado. (2021) (0)
- Angiopoietin-like ptotein 4 and 8 (ANGPTL4 and ANGPTL8) in human fetal liver are dysregulated by in utero exposure to maternal smoking (2018) (0)
- First Characterization of AKB-48 Metabolism, a Novel Synthetic Cannabinoid, Using Human Hepatocytes and High-Resolution Mass Spectrometry (2013) (0)
- Kratom Withdrawal: Discussions and Conclusions of a Scientific Expert Forum (2023) (0)
- Erratum to "Miniaturized extraction method for analysis of synthetic opioids in urine by microextraction with packed sorbent and liquid chromatography-tandem mass spectrometry" [J. Chromatogr. A 1624 (2020) 461241]. (2020) (0)
- S.13.02 Pharmacology of novel synthetic stimulants structurally related to the "bath salts” constituent 3,4-methylenedioxypyrovalerone (MDPV) (2017) (0)
- Methamphetamine Exposure, Polydrug Exposure, and Poverty on Intrauterine The Infant Development, Environment, and Lifestyle Study: Effects of Prenatal (2008) (0)
- Simultaneous Determination of Ag-Tetrahydrocannabinol (2001) (0)
- Erratum to: Modelling foetal exposure to maternal smoking using hepatoblasts from pluripotent stem cells (2017) (0)
- Maternal smoking and changes in drug metabolising enzymes in the human fetus (2018) (0)
- New Psychoactive Substances Intoxications and Fatalities during the COVID-19 Epidemic (2023) (0)
- In Vitro and In Vivo Human Metabolism of Synthetic Cannabinoids FDU-PB-22 and FUB-PB-22 (2016) (0)
- 1 Urine Drug Testing of Chronic Pain Patients. V. Prevalence of Propoxyphene Following its Withdrawal from (2013) (0)
- Hair toxicology identifies greater substance use than self-report in high-risk 9-13 year-olds in the ABCD Study (2021) (0)
- In reply. (2014) (0)
- In Vivo Toxicokinetics of Novel Psychoactive Substances (NPS) in Rats (2015) (0)
- Nasal Accumulation and Metabolism of Δ9-Tetrahydrocannabinol Following Aerosol (‘Vaping’) Administration in Adolescent Rats (2022) (0)
- Nasal accumulation and metabolism of Δ9-tetrahydrocannabinol following aerosol ('vaping') administration in an adolescent rat model. (2022) (0)
- S25-3Novel psychoactive substances: Epidemiology, mechanisms of action, and human metabolism of synthetic cannabinoids (2016) (0)
- Effects of subtoxic 3-methylmethcathinone concentrations on neuronal cell electrical properties (2022) (0)
- In silico prediction, human hepatocyte metabolism, LC-HRMS/MS analysis, and targeted/nontargeted data-mining to characterize 4-acetoxy-N,N-diisopropyl-tryptamine metabolism (2022) (0)
- Cannabidiol, Δ9-tetrahydrocannabinol, and metabolites in human blood by volumetric absorptive microsampling (VAMS) and LC-MS/MS (2022) (0)
- Review for "Maternal‐fetal transmission of delta‐9‐tetrahydrocannabinol (THC) and its metabolites following inhalation and injection exposure during pregnancy in rats" (2021) (0)
- Cannabinoids Pharmacology, Abuse, and Addiction (2016) (0)
- 27 Amphetamine Excretion Following Administration of Adderall (2010) (0)
- Growth and neurodevelopmental outcomes in children prenatally exposed to methamphetamine (2012) (0)
- Salivary uric acid concentrations in young children exposed to prenatal substance use are related to emotion and behavioral problems (2019) (0)
- Modelling foetal exposure to maternal smoking using hepatoblasts from pluripotent stem cells (2017) (0)
- Nicotine metabolite ratio in plasma and urine by different analytical methods and laboratories: Implications for clinical implementation (2015) (0)
- Automated and semi-automated screening, LCMSMS confirmation and human hepatocyte high-resolution metabolism studies of synthetic cannabinoids (2013) (0)
- Associations between prenatal and postnatal substance exposure and salivary C-reactive protein in early childhood. (2022) (0)
- Pentylindole/Pentylindazole Synthetic Cannabinoids and Their 5-Fluoro Analogs Produce Different Primary Metabolites: Metabolite Profiling for AB-PINACA and 5F-AB-PINACA (2015) (0)
- Studies of High-Dose Buprenorphine in Humans (2017) (0)
This paper list is powered by the following services:
Other Resources About Marilyn Huestis
What Schools Are Affiliated With Marilyn Huestis?
Marilyn Huestis is affiliated with the following schools:
